Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Biomolecules
Special Issues
Molecular, Cellular, and Blood Biomarkers in Diagnosis, Prognosis, Monitoring, and...
share announcement

Molecular, Cellular, and Blood Biomarkers in Diagnosis, Prognosis, Monitoring, and Treatment: 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 1783

Special Issue Editors

Dr. Jordi Camps

E-Mail Website
Guest Editor
United de Recerca Biomèdica, Universitat Rovira i Virgili, Reus, Spain
Interests: oxidative stress; inflammation; metabolism; non-communicable diseases; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Isabel Fort Gallifa

E-Mail Website
Guest Editor
Clinical Laboratory of the Hospital Universitari Joan XXIII de Tarragona, Universitat Rovira i Virgili, Tarragona, Spain
Interests: oxidative stress
Special Issues, Collections and Topics in MDPI journals
Dr. Xavier Gabaldó Barrios

E-Mail Website
Guest Editor
Clinical Laboratory of the Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili, Reus, Spain
Interests: biomarkers; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are pivotal in modern medicine, serving as vital clues that unlock the mysteries of diseases. By detecting subtle molecular, cellular, or biochemical changes, biomarkers enable early diagnosis, personalized treatment strategies, and precise monitoring of therapeutic responses. They revolutionize patient care by enhancing accuracy, efficiency, and patient outcomes. Biomarkers also drive drug discovery, guiding the development of targeted therapies and facilitating clinical trials. In essence, biomarkers illuminate the path towards a future of healthcare where interventions are precisely tailored to individual needs, leading to improved quality of life and better health outcomes for all. Presently, biomarker research occupies the focal point where biology and medicine converge.

By contributing to this Special Issue, you will have the opportunity to share your findings on the latest developments in molecular, cellular, and blood biomarkers. This platform also offers a unique opportunity for collaboration and networking with fellow researchers in this field. Whether you are exploring cancer signatures, unraveling neurodegenerative disease pathways, or investigating the biomarkers of any other non-communicable or infectious disease, your work has the potential to impact patient care. Moreover, your contributions will help advance diagnostic tools, prognostic models, monitoring techniques, and targeted therapies.

We encourage scientists like you to send original research articles and reviews that will cover any aspect of the effects of molecular, cellular, and blood biomarkers in diagnosis, prognosis, monitoring, and treatment. Your unique perspectives and insights are invaluable in our collective effort to translate research into tangible benefits for patients. Together, we can make a significant difference in patient care.

Dr. Jordi Camps
Dr. Isabel Fort Gallifa
Dr. Xavier Gabaldó Barrios
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • infectious diseases
  • laboratory medicine
  • non-communicable diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 4073 KB  
Article
Post-Radiotherapy Changes in Circulating Dodecanoic Acid Identify Metabolic Phenotypes Associated with Recurrence in Breast Cancer
by Andrea Jiménez-Franco, Vicente Cambra-Cortés, Raquel García-Pablo, Marta Canela-Capdevila, Rocío Benavides-Villarreal, Xavier Gabaldó-Barrios, Isabel Fort-Gallifa, Jordi Camps, Jorge Joven and Meritxell Arenas
Biomolecules 2026, 16(3), 355; https://doi.org/10.3390/biom16030355 - 26 Feb 2026
Viewed by 502
Abstract
Research on biomarkers reflecting tumor biology and systemic metabolism is crucial for improving the accuracy and personalization of breast cancer (BC) prognosis. We investigated circulating dodecanoic acid in 229 patients undergoing radiotherapy (RT) and assessed its association with progression-free survival and overall survival [...] Read more.
Research on biomarkers reflecting tumor biology and systemic metabolism is crucial for improving the accuracy and personalization of breast cancer (BC) prognosis. We investigated circulating dodecanoic acid in 229 patients undergoing radiotherapy (RT) and assessed its association with progression-free survival and overall survival over six years. Patients were classified into two phenotypes based on post-RT changes in dodecanoic acid: The Increase Phenotype (IP) had lower baseline concentrations and showed a post-RT rise, whereas the Decrease Phenotype (DP) had higher pre-RT levels and declined after treatment. Dodecanoic acid levels were lower in tumors than in peritumoral samples, and their association with phenotypes varied by sampling region, suggesting that systemic changes reflect broader metabolic adaptations rather than local tissue concentrations. Post-RT increases in dodecanoic acid were associated with higher paraoxonase-1 activity, suggesting a link with antioxidant status. Patients in the IP group had a significantly lower risk of progression than those in the DP group, whereas no significant differences in overall survival were observed. These findings highlight the potential utility of dodecanoic acid measurement as a prognostic biomarker and suggest that modulating fatty acid metabolism could be explored as a therapeutic strategy. Full article
(This article belongs to the Special Issue Molecular, Cellular, and Blood Biomarkers in Diagnosis, Prognosis, Monitoring, and Treatment: 2nd Edition)
►▼ Show Figures

Figure 1

28 pages, 5788 KB  
Article
Elevated Epithelial Splicing Regulatory Protein 1 Expression in Biliary Atresia Indicates Its Potential as a Molecular Marker
by Giorgia Ammirata, Victor Navarro-Tableros, Marta Manco, Ghania Zubair, Luca Di Costanzo, Luigi Chiusa, Alice Ponte, Michele Pinon, Renato Romagnoli, Ralf Weiskirchen, Paola Cassoni, Pier Luigi Calvo, Ugo Ala, Fiorella Altruda and Sharmila Fagoonee
Biomolecules 2026, 16(1), 9; https://doi.org/10.3390/biom16010009 - 19 Dec 2025
Viewed by 982
Abstract
Cholangiopathies encompass a wide range of chronic liver diseases that target biliary epithelial cells, leading to significant morbidity and mortality due to their progressive nature, limited treatment options, and complex clinical management. Currently, clinically validated biomarkers capable of distinguishing obstructive cholangiopathies, such as [...] Read more.
Cholangiopathies encompass a wide range of chronic liver diseases that target biliary epithelial cells, leading to significant morbidity and mortality due to their progressive nature, limited treatment options, and complex clinical management. Currently, clinically validated biomarkers capable of distinguishing obstructive cholangiopathies, such as biliary atresia (BA), from other cholangiopathies are lacking, hindering timely intervention. RNA-binding proteins (RBPs) have been increasingly linked to human diseases but their roles in cholangiopathies remain underexplored. We assessed the expression of the RBP epithelial splicing regulatory protein 1 (ESRP1) in murine models of cholangiopathies and in the human system. Our findings demonstrate that ESRP1 is highly and specifically expressed in cholestatic liver injury models, including bile duct-ligated, diethoxycarboncyl-1,4-dihydrocollidine-treated, and Mdr2−/− mice when compared with other liver injury models. Importantly, ESRP1 is markedly elevated in the livers of patients with BA and cystic fibrosis-related liver disease, localizing to cholangiocytes and peri-biliary hepatic cells, but is minimal in primary sclerosing cholangitis and primary biliary cholangitis. Moreover, patient-derived BA organoids and biliatresone-treated healthy organoids also display ESRP1 expression. Bioinformatics analysis further implicates ESRP1 in key cholangiopathy-associated pathways, warranting deeper mechanistic investigation. Thus, ESRP1 holds potential as a molecular marker for obstructive cholangiopathies, warranting further mechanistic studies. Full article
(This article belongs to the Special Issue Molecular, Cellular, and Blood Biomarkers in Diagnosis, Prognosis, Monitoring, and Treatment: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop